The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.

Author: AbubakarMurtala B, GanSiew Hua, WeiKeat

Paper Details 
Original Abstract of the Article :
Breast cancer is a common cause of cancer mortality among women. Several genetic factors have been implicated in its development. Current treatment guidelines for estrogen receptor-positive breast cancer recommend that anastrozole [or any of the other two aromatase inhibitors (letrozole and exemesta...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1097/FPC.0000000000000092

データ提供:米国国立医学図書館(NLM)

Genetic Polymorphisms and Anastrozole Treatment in Breast Cancer

This study delves into the complex interplay between genetics and drug response, examining the influence of genetic polymorphisms on the efficacy and side effects of anastrozole, a medication commonly used to treat estrogen receptor-positive breast cancer. The researchers explored the role of genetic variations in the genes encoding aromatase, the drug target, and its metabolizing enzymes (CYP3A and UGT1A). The study suggests that these genetic variations may contribute to the interindividual variability in anastrozole's effectiveness and tolerability.

Personalized Medicine: Tailoring Treatment to Individual Genetics

This study emphasizes the importance of personalized medicine in tailoring treatment to individual genetic profiles. The researchers suggest that understanding genetic variations in patients with breast cancer could help predict their response to anastrozole, potentially leading to more effective and personalized treatment approaches.

Understanding Drug Variability and Optimizing Breast Cancer Treatment

This study highlights the importance of understanding the role of genetic polymorphisms in influencing drug response. It suggests that incorporating genetic testing into breast cancer treatment could lead to more personalized and effective therapies, potentially improving outcomes for patients.

Dr. Camel's Conclusion

This study delves into the fascinating world of pharmacogenomics, exploring the influence of genetic polymorphisms on the efficacy and side effects of anastrozole. The findings underscore the importance of considering individual genetic profiles when developing personalized treatment strategies for breast cancer patients, potentially leading to improved outcomes and a more tailored approach to care.
Date :
  1. Date Completed 2015-11-03
  2. Date Revised 2019-03-28
Further Info :

Pubmed ID

25203739

DOI: Digital Object Identifier

10.1097/FPC.0000000000000092

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.